Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from Mechanistic modeling of tumor immune microenvironment reveals strategies to enhance antibody-drug conjugates’ efficacy. Local targets link to admitted publications; unresolved targets remain external evidence.
Antibody–Drug Conjugates (ADCs): current and future biopharmaceuticals
10.1186/s13045-025-01704-3 · 2025 · External reference
10.1038/s41571-023-00850-2
10.1038/s41571-023-00850-2 · External reference
10.1038/s41573-024-00896-6
10.1038/s41573-024-00896-6 · External reference
Preclinical Characterization and Phase I Study of an Anti-HER2-TLR7 Immune-Stimulator Antibody Conjugate in Patients with HER2+ Malignancies
10.1158/2326-6066.cir-21-0722 · 2022 · External reference
209P Interim results of a phase I/Ib study of SBT6050 monotherapy and pembrolizumab combination in patients with advanced HER2-expressing or amplified solid tumors
10.1016/j.annonc.2021.08.491 · 2021 · External reference
164P Preliminary results from a phase I/II study of BDC-1001, a novel HER2 targeting TLR7/8 immune-stimulating antibody conjugate (ISAC), in patients (pts) with advanced HER2-expressing solid tumors
10.1016/j.annonc.2021.10.183 · 2021 · External reference
A phase 1/2 study of a first-in-human immune-stimulating antibody conjugate (ISAC) BDC-1001 in patients with advanced HER2-expressing solid tumors
10.1200/jco.2023.41.16_suppl.2538 · 2023 · External reference
Bispecific antibodies: advancing precision oncology
10.1016/j.trecan.2024.07.002 · 2024 · External reference
Antibody-drug conjugates in breast cancer: overcoming resistance and boosting immune response
10.1172/jci172156 · 2023 · External reference
10.1038/s41571-021-00470-8
10.1038/s41571-021-00470-8 · External reference
Immune Modulating Antibody–Drug Conjugate (IM-ADC) for Cancer Immunotherapy
10.1021/acs.jmedchem.1c00961 · 2021 · External reference
10.1038/s41571-019-0308-z
10.1038/s41571-019-0308-z · External reference
10.1146/annurev-bioeng-110220-115419
10.1146/annurev-bioeng-110220-115419 · External reference
10.1200/jco.2012.46.3653
10.1200/jco.2012.46.3653 · External reference
10.1038/nrclinonc.2010.139
10.1038/nrclinonc.2010.139 · External reference
Capturing the Magic Bullet: Pharmacokinetic Principles and Modeling of Antibody-Drug Conjugates
10.1208/s12248-020-00475-8 · 2020 · External reference
Pharmacokinetic analysis of the perivascular distribution of bifunctional antibodies and haptens: comparison with experimental data
1992 · External reference
Pharmacokinetic analysis of two-step approaches using bifunctional and enzyme-conjugated antibodies
1991 · External reference
10.1124/dmd.117.076414
10.1124/dmd.117.076414 · External reference
10.1016/j.xphs.2019.01.034
10.1016/j.xphs.2019.01.034 · External reference
Receptor-Mediated Endocytosis Modeling Of Antibody-Drug Conjugates To The Released Payload Within The Intracellular Space Considering Target Antigen Expression Levels
10.11948/20190232 · 2020 · External reference
A mechanistic pharmacokinetic model elucidating the disposition of trastuzumab emtansine (T-DM1), an antibody-drug conjugate (ADC) for treatment of metastatic breast cancer
10.1208/s12248-014-9618-3 · 2014 · External reference
10.1007/s10928-010-9156-2
10.1007/s10928-010-9156-2 · External reference
10.1007/s10928-012-9276-y
10.1007/s10928-012-9276-y · External reference
Multiscale Modeling of Antibody-Drug Conjugates: Connecting Tissue and Cellular Distribution to Whole Animal Pharmacokinetics and Potential Implications for Efficacy
10.1208/s12248-016-9940-z · 2016 · External reference
A Systems Pharmacology Model for Drug Delivery to Solid Tumors by Antibody-Drug Conjugates: Implications for Bystander Effects
10.1208/s12248-019-0390-2 · 2020 · External reference
Investigations of Influence of Antibody Binding Kinetics on Tumor Distribution and Anti-Tumor Efficacy
10.1208/s12248-025-01076-z · 2025 · External reference
Quantitative evaluation of trastuzumab deruxtecan pharmacokinetics and pharmacodynamics in mouse models of varying degrees of HER2 expression
10.1002/psp4.13133 · 2024 · External reference
Development of a minimal physiologically-based pharmacokinetic/pharmacodynamic model to characterize target cell depletion and cytokine release for T cell-redirecting bispecific agents in humans
10.1016/j.ejps.2020.105260 · 2020 · External reference
Leveraging a physiologically-based quantitative translational modeling platform for designing B cell maturation antigen-targeting bispecific T cell engagers for treatment of multiple myeloma
10.1371/journal.pcbi.1009715 · 2022 · External reference
Systems‐based digital twins to help characterize clinical dose–response and propose predictive biomarkers in a Phase I study of bispecific antibody, mosunetuzumab, in NHL
10.1111/cts.13501 · 2023 · External reference
A Mechanistic Physiologically‐ Based Pharmacokinetic Platform Model to Guide Adult and Pediatric Intravenous and Subcutaneous Dosing for Bispecific T Cell Engagers
10.1002/cpt.3056 · 2024 · External reference
Whole-Body Physiologically Based Pharmacokinetic Modeling Framework for Tissue Target Engagement of CD3 Bispecific Antibodies
10.3390/pharmaceutics17040500 · 2025 · External reference
Investigating the synergistic effects of immunotherapy and normalization treatment in modulating tumor microenvironment and enhancing treatment efficacy
10.1016/j.jtbi.2024.111768 · 2024 · External reference
Mathematical modeling of intratumoral immunotherapy yields strategies to improve the treatment outcomes
10.1371/journal.pcbi.1011740 · 2023 · External reference
Inducing Biomechanical Heterogeneity in Brain Tumor Modeling by MR Elastography: Effects on Tumor Growth, Vascular Density and Delivery of Therapeutics
10.3390/cancers14040884 · 2022 · External reference
10.1016/0026-2862(89)90074-5
10.1016/0026-2862(89)90074-5 · External reference
10.1016/0026-2862(90)90023-k
10.1016/0026-2862(90)90023-k · External reference
Enhancing KDM5A and TLR activity improves the response to immune checkpoint blockade
10.1126/scitranslmed.aax2282 · 2020 · External reference
10.1073/pnas.081626898
10.1073/pnas.081626898 · External reference
10.1158/1535-7163.mct-09-0195
10.1158/1535-7163.mct-09-0195 · External reference
10.1126/science.aaw7875
10.1126/science.aaw7875 · External reference
10.1146/annurev-physiol-020518-114700
10.1146/annurev-physiol-020518-114700 · External reference
10.1073/pnas.1318022110
10.1073/pnas.1318022110 · External reference
Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Phase 2 Clinical Trial
10.1001/jamaoncol.2019.0892 · 2019 · External reference
10.1158/1078-0432.ccr-24-0246
10.1158/1078-0432.ccr-24-0246 · External reference
10.1073/pnas.1318415110
10.1073/pnas.1318415110 · External reference
10.1016/j.addr.2021.05.013
10.1016/j.addr.2021.05.013 · External reference
10.1158/1078-0432.ccr-07-1443
10.1158/1078-0432.ccr-07-1443 · External reference
